A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Non-Biologic Lupus Standard of Care

Brief description of study

The purpose of the study is to investigate if the investigational study drug BIIB059 can reduce disease activity and inflammation in people with active systemic lupus erythematosus (SLE) compared to a placebo. “Investigational” means that the study drug is currently being tested. BIIB059 is a type of antibody (a substance that is made by the immune system) that has been developed in a lab to be used in people. The study drug has been developed to target certain cells that are thought to play a role in the development of lupus. It is hoped the study drug can improve symptoms in people who have SLE.

Clinical Study Identifier: s21-00354
ClinicalTrials.gov Identifier: NCT04895241
Principal Investigator: David H. Goddard.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.